Supernus Pharmaceuticals Inc (SUPN)

Total asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	661,817	654,387	632,578	598,906	607,521	619,414	641,163	674,751	673,056	651,277	618,187	585,808	560,079	545,016	551,524	536,576	506,717	465,383	418,476	402,257
Total assets	US$ in thousands	1,368,070	1,342,700	1,315,830	1,304,090	1,277,670	1,285,160	1,293,100	1,791,810	1,702,510	1,693,130	1,694,970	1,639,520	1,689,150	1,555,040	1,573,060	1,507,440	1,504,100	1,510,020	1,491,020	1,189,870
Total asset turnover		0.48	0.49	0.48	0.46	0.48	0.48	0.50	0.38	0.40	0.38	0.36	0.36	0.33	0.35	0.35	0.36	0.34	0.31	0.28	0.34

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $661,817K ÷ $1,368,070K
= 0.48

Supernus Pharmaceuticals Inc's total asset turnover has shown fluctuations over the period under review. The ratio started at 0.34 as of March 31, 2020, decreased to 0.28 by June 30, 2020, and then gradually increased to reach 0.40 by December 31, 2022. There was a notable spike to 0.50 by June 30, 2023, indicating a significant improvement in the company's efficiency in generating sales relative to its total assets. Subsequently, the ratio slightly decreased to 0.46 by March 31, 2024, before stabilizing around 0.48 in the last three quarters of 2024.

Overall, the trend in total asset turnover suggests that Supernus Pharmaceuticals Inc has been effectively utilizing its assets to generate revenue, with fluctuations possibly influenced by changes in the company's operating performance or asset base during the period. A higher total asset turnover indicates that the company is generating more sales per dollar of assets, reflecting better efficiency in asset utilization.